Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
M28z1XXPD1DNR CAR T Cell Therapy in Mesothelin-Positive Esophagogastric Adenocarcinoma or Malignant Peritoneal Mesothelioma
NCT06623396Phase 1Recruiting
- Sponsor
- Memorial Sloan Kettering Cancer Center
- Start
- Sep 2024
- Primary completion
- Sep 2028
- Modality
- Gene Editing, Gene Silencing, CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label trial of M28z1XXPD1DNR in Esophago-Gastric Adenocarcinoma and malignant peritoneal mesothelioma (MPM) (2 arms), sponsored by Memorial Sloan Kettering Cancer Center. Primary endpoints: Number of treatment-emergent adverse events at 1 year and Maximum Tolerated Dose up to 1 year. Started Sep 2024; status: recruiting.
02
Drugs
M28z1XXPD1DNR
03
Conditions
Esophago-Gastric Adenocarcinomamalignant peritoneal mesothelioma (MPM)
Beyond the preview
Go deeper on NCT06623396.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06623396.